Clinical Applications of Molecular Biomarkers in Prostate Cancer
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disea...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/6/1550 |
| _version_ | 1797565512708784128 |
|---|---|
| author | Felipe Couñago Fernando López-Campos Ana Aurora Díaz-Gavela Elena Almagro Esaú Fenández-Pascual Iván Henríquez Rebeca Lozano Estefanía Linares Espinós Alfonso Gómez-Iturriaga Guillermo de Velasco Luis Miguel Quintana Franco Ignacio Rodríguez-Melcón José López-Torrecilla Daniel E. Spratt Luis Leonardo Guerrero Juan Ignacio Martínez-Salamanca Elia del Cerro |
| author_facet | Felipe Couñago Fernando López-Campos Ana Aurora Díaz-Gavela Elena Almagro Esaú Fenández-Pascual Iván Henríquez Rebeca Lozano Estefanía Linares Espinós Alfonso Gómez-Iturriaga Guillermo de Velasco Luis Miguel Quintana Franco Ignacio Rodríguez-Melcón José López-Torrecilla Daniel E. Spratt Luis Leonardo Guerrero Juan Ignacio Martínez-Salamanca Elia del Cerro |
| author_sort | Felipe Couñago |
| collection | DOAJ |
| description | There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the differential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical practice. |
| first_indexed | 2024-03-10T19:14:13Z |
| format | Article |
| id | doaj.art-a2327e998203411392132a70fad07155 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:14:13Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a2327e998203411392132a70fad071552023-11-20T03:35:22ZengMDPI AGCancers2072-66942020-06-01126155010.3390/cancers12061550Clinical Applications of Molecular Biomarkers in Prostate CancerFelipe Couñago0Fernando López-Campos1Ana Aurora Díaz-Gavela2Elena Almagro3Esaú Fenández-Pascual4Iván Henríquez5Rebeca Lozano6Estefanía Linares Espinós7Alfonso Gómez-Iturriaga8Guillermo de Velasco9Luis Miguel Quintana Franco10Ignacio Rodríguez-Melcón11José López-Torrecilla12Daniel E. Spratt13Luis Leonardo Guerrero14Juan Ignacio Martínez-Salamanca15Elia del Cerro16Radiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, SpainRadiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, SpainRadiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, SpainMedical Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, SpainLyx Institute of Urology, Universidad Francisco de Vitoria, 28006 Madrid, SpainRadiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, SpainProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 28029 Madrid, SpainLyx Institute of Urology, Universidad Francisco de Vitoria, 28006 Madrid, SpainCruces University Hospital, Biocruces Heath Research Institute, 48903 Barakaldo, SpainMedical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, SpainDepartment of Urology, Hospital Universitario La Paz, 28046 Madrid, SpainRadiation Oncology, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, SpainRadiation Oncology-ERESA, Hospital General Universitario de Valencia, 46014 Valencia, SpainDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USARadiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, SpainLyx Institute of Urology, Universidad Francisco de Vitoria, 28006 Madrid, SpainRadiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, SpainThere is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the differential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical practice.https://www.mdpi.com/2072-6694/12/6/1550biomarkersDNA repairgene panelsgenetic testinggermline mutationprecision medicine |
| spellingShingle | Felipe Couñago Fernando López-Campos Ana Aurora Díaz-Gavela Elena Almagro Esaú Fenández-Pascual Iván Henríquez Rebeca Lozano Estefanía Linares Espinós Alfonso Gómez-Iturriaga Guillermo de Velasco Luis Miguel Quintana Franco Ignacio Rodríguez-Melcón José López-Torrecilla Daniel E. Spratt Luis Leonardo Guerrero Juan Ignacio Martínez-Salamanca Elia del Cerro Clinical Applications of Molecular Biomarkers in Prostate Cancer Cancers biomarkers DNA repair gene panels genetic testing germline mutation precision medicine |
| title | Clinical Applications of Molecular Biomarkers in Prostate Cancer |
| title_full | Clinical Applications of Molecular Biomarkers in Prostate Cancer |
| title_fullStr | Clinical Applications of Molecular Biomarkers in Prostate Cancer |
| title_full_unstemmed | Clinical Applications of Molecular Biomarkers in Prostate Cancer |
| title_short | Clinical Applications of Molecular Biomarkers in Prostate Cancer |
| title_sort | clinical applications of molecular biomarkers in prostate cancer |
| topic | biomarkers DNA repair gene panels genetic testing germline mutation precision medicine |
| url | https://www.mdpi.com/2072-6694/12/6/1550 |
| work_keys_str_mv | AT felipecounago clinicalapplicationsofmolecularbiomarkersinprostatecancer AT fernandolopezcampos clinicalapplicationsofmolecularbiomarkersinprostatecancer AT anaauroradiazgavela clinicalapplicationsofmolecularbiomarkersinprostatecancer AT elenaalmagro clinicalapplicationsofmolecularbiomarkersinprostatecancer AT esaufenandezpascual clinicalapplicationsofmolecularbiomarkersinprostatecancer AT ivanhenriquez clinicalapplicationsofmolecularbiomarkersinprostatecancer AT rebecalozano clinicalapplicationsofmolecularbiomarkersinprostatecancer AT estefanialinaresespinos clinicalapplicationsofmolecularbiomarkersinprostatecancer AT alfonsogomeziturriaga clinicalapplicationsofmolecularbiomarkersinprostatecancer AT guillermodevelasco clinicalapplicationsofmolecularbiomarkersinprostatecancer AT luismiguelquintanafranco clinicalapplicationsofmolecularbiomarkersinprostatecancer AT ignaciorodriguezmelcon clinicalapplicationsofmolecularbiomarkersinprostatecancer AT joselopeztorrecilla clinicalapplicationsofmolecularbiomarkersinprostatecancer AT danielespratt clinicalapplicationsofmolecularbiomarkersinprostatecancer AT luisleonardoguerrero clinicalapplicationsofmolecularbiomarkersinprostatecancer AT juanignaciomartinezsalamanca clinicalapplicationsofmolecularbiomarkersinprostatecancer AT eliadelcerro clinicalapplicationsofmolecularbiomarkersinprostatecancer |